Literature DB >> 16638707

Portosystemic myelopathy: spastic paraparesis after portosystemic shunting.

Harold O Conn1, Martin Rössle, Lewis Levy, Franz X Glocker.   

Abstract

Portosystemic encephalopathy (PSE) is a well-known, common complication of portal hypertension. It is thought to be caused by nitrogenous substances such as ammonia, which are normally cleared from the blood stream by the liver. In cirrhosis and other hepatic disorders with portosystemic shunting (PSS)-- either surgical portosystemic anastomoses (PSA) or spontaneous PSS-- the collateral vessels bypass the liver allowing the accumulation of toxic, ammoniacal substances in the blood and tissues. PSE is characterized by encephalopathy; portosystemic myelopathy (PSM) is characterized by paresis of the extremities, Babinski signs and muscle spasticity in patients with cirrhosis and/or PSS. Usually only the lower extremities are involved. This report presents the first case of this syndrome observed 5 years after a transjugular intrahepatic portosystemic shunt. The 31 year old man with chronic Hepatitis B developed complete spastic paraparesis within 4 weeks after onset of clinical/neurological symptoms, accompanied by an episode of severe hepatic encephalopathy. The transcortical magnetic stimulation showed normal motoric stimulation times to the abductor digiti minimi muscles but no stimulation to the tibialis muscles was seen. Lumbar stimulation to the tibialis muscles, however, was normal. This indicates loss of motor neurons in the spinal cord, a characteristic finding in patients with portosystemic myelopathy. We performed a search of the literature for all reported cases of cirrhosis and/or PSS that developed PSM. However, the intervals between the construction of a shunt and the diagnosis of portosystemic myelopathy were shorter in total portacaval shunts (median 16 months) than in partial, non-portacaval shunts (median 60 months, p < 0.01). This suggests that not only the shunt itself but also the shunted volume contributes to the development of the syndrome Sixty-one patients with PSM have been reported in the literature since 1944. PSE had developed before PSM in almost all cases. PSM occurred from 1 month to 10 years after the creation of portacaval anastomoses (PCA) or splenorenal shunts (SRS) or in cirrhotic patients without shunts. No one type of liver disease or type of shunt appears to predispose to PSM. The mechanisms of PSE and PSM are thought to be similar and of nitrogenous origin, but their pathogenesis remains unknown. Lathyrism, a toxic syndrome with similar symptoms and signs, is caused by the ingestion of a legume, Lathyrus sativa, which contains beta-N-oxalo-L amino-L-alanine (BOAA). This animal model with or without BOAA appears to offer a reliable way of studying PSM experimentally.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638707     DOI: 10.1080/00365520500318932

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Acquired hepatocerebral degeneration.

Authors:  Joseph Ferrara; Joseph Jankovic
Journal:  J Neurol       Date:  2009-02-17       Impact factor: 4.849

2.  Portosystemic myelopathy: a rare neurological presentation of portosystemic shunts.

Authors:  Prasanna K S Rao; Keyur A Sheth; Raghunandan Nadig; Mallikarjun Patil; Adarsh K Channagiri
Journal:  J Clin Exp Hepatol       Date:  2012-10-22

3.  Management of surgical splenorenal shunt-related hepatic myelopathy with endovascular interventional techniques.

Authors:  Mao-Qiang Wang; Feng-Yong Liu; Feng Duan
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 4.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 5.  Spinal cord involvement in patients with cirrhosis.

Authors:  Raffaele Nardone; Yvonne Höller; Monica Storti; Piergiorgio Lochner; Frediano Tezzon; Stefan Golaszewski; Francesco Brigo; Eugen Trinka
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 6.  Human alcohol-related neuropathology.

Authors:  Suzanne M de la Monte; Jillian J Kril
Journal:  Acta Neuropathol       Date:  2013-12-27       Impact factor: 17.088

7.  Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China.

Authors:  Hongwei Zhao; Zhendong Yue; Lei Wang; Zhenhua Fan; Fuliang He; Xiaoqun Dong; Fuquan Liu
Journal:  Sci Rep       Date:  2018-10-12       Impact factor: 4.379

8.  Regional gray matter abnormality in hepatic myelopathy patients after transjugular intrahepatic portosystemic shunt: a voxel-based morphometry study.

Authors:  Kang Liu; Gang Chen; Shu-Yao Ren; Yuan-Qiang Zhu; Tian-Lei Yu; Ping Tian; Chen Li; Yi-Bin Xi; Zheng-Yu Wang; Jian-Jun Ye; Guo-Hong Han; Hong Yin
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.